

LISTE des PUBLICATIONS SCIENTIFIQUES extraites de SIGAPS

ANNEE 2016

AlyamiM ; LundbergP ; KepenekianV ; GoéréD ; BerederJM ; Msika et al. , Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis in the Elderly: A Case-Controlled, Multicenter Study., *Ann. Surg. Oncol.*, 2016, 23, 737-745

AtallahV ; HonoreC ; OrbachD ; HelfreS ; DucassouA ; Thomas et al. , Role of Adjuvant Radiation Therapy After Surgery for Abdominal Desmoplastic Small Round Cell Tumors., *Int. J. Radiat. Oncol. Biol. Phys.*, 2016, 95, 1244-53

Aumont, M , [What is the role of intraoperative radiotherapy in breast cancer treatment?], *Cancer Radiother*, 2016, 20, 583-6

AwadaA ; CamponeM ; VargaA ; AftimosP ; FrenelJS ; Bahleda et al. , An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors., *Anticancer Drugs*, 2016, 27, 342-8

AyedT ; PilméJ ; Tézéd ; BassalF ; BarbetJ ; Chérel et al. , (211)At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds., *Eur J Med Chem*, 2016, 116, 156-164

AzaïsH ; SchmittC ; TardivelM ; KerdraonO ; StallivieriA ; Frochot et al. , Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study., *Photodiagnosis Photodyn Ther*, 2016, 13, 130-8

Bachelot, T ; Campone, M ; Tredan, O , PI3K targeting in breast cancer: the end of the beginning?, *Lancet Oncol.*, 2016, 17, 696-697

BadoerC ; GarrecC ; GoossensD ; EllisonG ; MillsJ ; Dzial et al. , Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples., *Oncotarget*, 2016, 7, 81357-81366

Baert-DesurmontS ; CharbonnierF ; HouivetE ; IppolitoL ; MauillonJ ; Bougeard et al. , Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk., *Eur. J. Hum. Genet.*, 2016, 24, 99-105

BaffertS ; AlranS ; FourchetteV ; TraoreMA ; SimondiC ; Mathevet et al. , Laparoscopic hysterectomy after concurrent radiochemotherapy in locally advanced cervical cancer compared to laparotomy: A multi institutional prospective pilot study of cost, surgical outcome and quality of life., *Eur J Surg Oncol*, 2016, 42, 391-9

BaillyC ; Bodet-MilinC ; CouespelS ; NecibH ; Kraeber-BodéréF ; Ansquer et al. , Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials., *PLoS ONE*, 2016, 11, e0159984

BaillyC ; CléryPF ; Faivre-ChauvetA ; BourgeoisM ; GuérardF ; Haddad et al. , Immuno-PET for Clinical Theranostic Approaches., *Int J Mol Sci*, 2016, 18,

BarbetJ ; ArlicotN ; GauglerMH ; ChérelM ; GuilloteauD ; Kraeber-Bodéré et al. , Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology., *Front Med (Lausanne)*, 2016, 3, 74

Barillot, I ; Mahé, MA ; Antoni, D ; Hennequin, C , [Radiotherapy of lymphomas]., *Cancer Radiother*, 2016, 20 Suppl, S244-8

BarillotI ; ChauvetB ; Hannoun LéviJM ; LisboaA ; LeroyT ; Mahé et al. , [The irradiation process]., *Cancer Radiother*, 2016, 20 Suppl, S8-S19

Barlesi F ; Mazieres J ; Merlio J P ; Debieuvre D ; Mosser J ; Lena et al. , Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)., *Lancet*, 2016, 387, 1415-1426

Bekkar S ; Gronnier C ; Renaud F ; Duhamel A ; Pasquer A ; Théreaux et al. , Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer., *Br J Surg*, 2016, 103, 855-62

Bennouna, J ; Moreno Vera, SR , Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress., *Future Oncol*, 2016, 12, 355-72

Bernadou G ; Camponé M ; Merlin J L ; Gouilleux-Gruart V ; Bachelot T ; Lokiec et al. , Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer., *Br J Clin Pharmacol*, 2016, 81, 941-8

Bertinchamp R ; Gérard L ; Boutboul D ; Malphettes M ; Fieschi C ; Oksenhendler et al. , Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency., *J Allergy Clin Immunol Pract*, 2016, 4, 1147-1157

Bertucci F ; Fekih M ; Autret A ; Petit T ; Dalenc F ; Levy et al. , Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study., *Lancet Oncol.*, 2016, 17, 600-11

Beuselinck B ; Jean-Baptiste J ; Schöffski P ; Couchy G ; Meiller C ; Rolland et al. , Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib., *BJU Int.*, 2016, 118, 890-901

Bibault J E ; Morelle M ; Perrier L ; Pommier P ; Boisselier P ; Coche-Dequéant et al. , Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer., *Cancer Radiother*, 2016, 20, 357-61

Blanchard P ; Faivre L ; Lesaunier F ; Salem N ; Mesgouez-Nebout N ; Deniau-Alexandre et al. , Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial., *Int. J. Radiat. Oncol. Biol. Phys.*, 2016, 94, 85-92

Bodet-Milin C ; Faivre-Chauvet A ; Carlier T ; Rauscher A ; Bourgeois M ; Cerato et al. , Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and <sup>68</sup>Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial., *J. Nucl. Med.*, 2016, 57, 1505-1511

Bodet-Milin C ; Kraeber-Bodéré F ; Eugène T ; Guérard F ; Gaschet J ; Bailly et al. , Radioimmunotherapy for Treatment of Acute Leukemia., *Semin Nucl Med*, 2016, 46, 135-46

Bonnefoi H ; Grellety T ; Tredan O ; Saghatchian M ; Dalenc F ; Mailliez et al. , A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)., *Ann. Oncol.*, 2016, 27, 812-8

Bouchet S ; Poulette S ; Titier K ; Moore N ; Lassalle R ; Abouelfath et al. , Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting., *Eur. J. Cancer*, 2016, 57, 31-8

Bourdon M ; Blanchin M ; Tessier P ; Camponé M ; Quéreux G ; Dravet et al. , Changes in quality of life after a diagnosis of cancer: a 2-year study comparing breast cancer and melanoma patients., *Qual Life Res*, 2016, 25, 1969-79

Brambilla E ; Le Teuff G ; Marguet S ; Lantuejoul S ; Dunant A ; Graziano et al. , Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer., *J. Clin. Oncol.*, 2016, 34, 1223-30

Brenner C ; Luciani J ; Bizet M ; Ndlovu M ; Josseaux E ; Dedeurwaerder et al. , The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent., *Oncotarget*, 2016, 7, 58939-58952

Bretagne C H ; Petitjean A ; Felix S ; Bedgedjian I ; Algros M P ; Delabrousse et al. , [Metastasis revealing malignant peritoneum mesothelioma: About the difficulty to identify the primary tumors]., *Ann Pathol*, 2016, 36, 105-10

CabartM ; FrénelJS ; CampionL ; RaméeJF ; DupuisO ; Senellart et al. , Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study., *Clin Colorectal Cancer*, 2016, 15, e165-e174

CabartM ; FrénelJS ; CampionL ; RaméeJF ; DupuisO ; Senellart et al. , [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer]., *Bull Cancer*, 2016, 103, 541-51

CarrieC ; HasbiniA ; de LarocheG ; RichaudP ; GuerifS ; Latorzeff et al. , Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial., *Lancet Oncol.*, 2016, 17, 747-756

Castellij ; FeuvretL ; HaomingQC ; BiauJ ; JouglarE ; Berger et al. , Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series., *J. Neurooncol.*, 2016, 129, 85-92

CauletM ; LecomteT ; BouchéO ; RollinJ ; Gouilleux-GruartV ; Azzopardi et al. , Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients., *Clin Pharmacokinet*, 2016, 55, 1381-1394

ChaudetA ; BouhoursG ; RineauE ; HamelJF ; LeblancD ; Steiger et al. , Impact of preoperative continuous femoral blockades on morphine consumption and morphine side effects in hip-fracture patients: A randomized, placebo-controlled study., *Anaesth Crit Care Pain Med*, 2016, 35, 37-43

CherayM ; PacaudR ; NadaradjaneA ; OliverL ; ValletteFM ; Cartron et al. , Specific Inhibition of DNMT3A/ISGF3? Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth., *Theranostics*, 2016, 6, 1988-1999

ChudeauN ; RaveauT ; CarlierL ; LeblancD ; BouhoursG ; Gagnadoux et al. , The STOP-BANG questionnaire and the risk of perioperative respiratory complications in urgent surgery patients: A prospective, observational study., *Anaesth Crit Care Pain Med*, 2016, 35, 347-353

Coqueret, O , Senescence: Adaptation to DNA repair targeting drugs?, *Cell Cycle*, 2016, 15, 2549-2550

CoxDG ; CurtitE ; RomieuG ; FumoleauP ; RiosM ; Bonnefoi et al. , GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients., *Oncotarget*, 2016, 7, 77358-77364

CuriglianoG ; RomieuG ; CamponeM ; DorvalT ; DuckL ; Canon et al. , A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer., *Breast Cancer Res. Treat.*, 2016, 156, 301-10

Dal Pra, A ; Locke, JA ; Borst, G ; Supiot, S ; Bristow, RG , Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer., *Front Oncol*, 2016, 6, 24

Dantal, J ; Campone, M , Daunting but worthy goal : reducing the de novo cancer incidence after transplantation., *Transplantation*, 2016, ,

Dantal, J ; Campone, M , Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation., *Transplantation*, 2016, 100, 2569-2583

DasSG ; RomagnoliM ; MinevaND ; Barillé-NionS ; JézéquelP ; Campone et al. , miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells., *Breast Cancer Res.*, 2016, 18, 40

de BockÉ ; HardouinJB ; BlanchinM ; Le NeelT ; KubisG ; Bonnaud-Antignac et al. , Rasch-family models are more valuable than score-based approaches for analysing longitudinal patient-reported outcomes with missing data., *Stat Methods Med Res*, 2016, 25, 2067-2087

de CrevoisierR ; ChauvetB ; BarillotI ; LafondC ; MahéM ; Delpon et al. , [Image-guided radiotherapy]., *Cancer Radiother*, 2016, 20 Suppl, S27-35

de MarinisF ; BriaE ; CiardielloF ; CrinòL ; DouillardJY ; Griesinger et al. , International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes., *J Thorac Oncol*, 2016, 11, 1153-69

DelalogeS ; BachelotT ; BidardFC ; EspieM ; BrainE ; Bonnefoi et al. , [Erratum to: "Breast cancer screening: On our way to the future" [*Bull. Cancer* 103 (2016) 753-763]]., *Bull Cancer*, 2016, 103, 951-952

DelalogeS ; BachelotT ; BidardFC ; EspieM ; BrainE ; Bonnefoi et al. , [Breast cancer screening: On our way to the future]., *Bull Cancer*, 2016, 103, 753-63

DelalogeS ; PérolD ; CourtinardC ; BrainE ; AsselainB ; Bachelot et al. , Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study., *Ann. Oncol.*, 2016, 27, 1725-32

DelhormeJB ; EliasD ; VaratharajahS ; BenhaimL ; DumontF ; Honoré et al. , Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei?, *Ann. Surg. Oncol.*, 2016, 23, 1618-24

DelponG ; EscandeA ; RuefT ; DarréonJ ; FontaineJ ; Noblet et al. , Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy., *Front Oncol*, 2016, 6, 178

DelponG ; Frelin-LabalmeAM ; HeinrichS ; BeaudouinV ; NobletC ; Begue et al. , [Small animal image-guided radiotherapy: A new era for preclinical studies]., *Cancer Radiother*, 2016, 20, 43-53

Demoor-Goldschmidt, C ; Agape, P ; Barillot, I ; Mahé, MA , [Radiotherapy in localized stages of follicular and diffuse non-Hodgkin's lymphomas]., *Cancer Radiother*, 2016, 20, 530-4

Demoor-GoldschmidtC ; ClaudeL ; CarrieC ; BolleS ; HelfreS ; Alapetite et al. , [French organization of paediatric radiation treatment: Results of a survey conducted by the radiotherapy Committee of the French Society of Paediatric Cancers (SFCE)]., *Cancer Radiother*, 2016, 20, 395-9

Demoor-GoldschmidtC ; SupiotS ; ClaudeL ; CarrieC ; MazonR ; Helfré et al. , [French experience in paediatric total body irradiation: A study from the radiotherapy committee of the Société française des cancers de l'enfant (SFCE)]., *Cancer Radiother*, 2016, 20, 304-7

DiérasV ; BachelotT ; CamponeM ; IsambertN ; JolyF ; Le Tourneau et al. , A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study., *Oncol Ther*, 2016, 4, 211-223

DorsoL ; Bigot-CorbelE ; AbadieJ ; DiabM ; GouardS ; Bruchertseifer et al. , Long-Term Toxicity of <sup>213</sup>Bi-Labelled BSA in Mice., *PLoS ONE*, 2016, 11, e0151330

du BoisA ; KristensenG ; Ray-CoquardI ; ReussA ; PignataS ; Colombo et al. , Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial., *Lancet Oncol.*, 2016, 17, 78-89

DuboisN ; RioE ; RipochéN ; Ferchaud-RoucherV ; GauglerMH ; Champion et al. , Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan., *Radiother Oncol*, 2016, 119, 229-35

Dufreneix, S ; Ostrowsky, A ; Rapp, B ; Daures, J ; Bordy, JM , Accuracy of a dose-area product compared to an absorbed dose to water at a point in a 2 cm diameter field., *Med Phys*, 2016, 43, 4085

DufreneixS ; OstrowskyA ; Le RoyM ; SommierL ; GouriouJ ; Delaunay et al. , Using a dose-area product for absolute measurements in small fields: a feasibility study., *Phys Med Biol*, 2016, 61, 650-62

DumarsC ; FoubertF ; TouchefeuY ; RegenetN ; SenellartH ; Matysiak-Budnik et al. , Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors?, *Endocrine*, 2016, 53, 395-401

Dumont, F ; Goéré, D ; Benhaim, L ; Honoré, C ; Elias, D , Laparoscopic single port pseudo-continent perineal colostomy., *J Visc Surg*, 2016, 153, 45-53

Duy VoD ; Rouaudi ; Le DevehatF ; GautierF ; Barillé-NionS ; Juin et al. , Preliminary Studies on the Activity of Mixed Polyphenol-Heterocyclic Systems Against B16-F10 Melanoma Cancer Cells., *Med Chem*, 2016, 12, 419-25

Eskian, M ; Khorasanizadeh, M ; Kraeber-Bodere, F ; Rezaei, N , Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response., *Crit. Rev. Oncol. Hematol.*, 2016, 107, 182-189

Fadous-KhaliféMC ; AloulouN ; JalboutM ; HadchityJ ; AftimosG ; Paris et al. , Krüppel-like factor 4: A new potential biomarker of lung cancer., *Mol Clin Oncol*, 2016, 5, 35-40

FerreroJM ; Hardy-BessardAC ; CapitainO ; LortholaryA ; SallesB ; Follana et al. , Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study., *Cancer*, 2016, 122, 3119-3126

FiteniF ; VernereyD ; BonnetainF ; VayletF ; SennélarthH ; Trédaniel et al. , Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients., *Eur. J. Cancer*, 2016, 52, 120-8

FleurenceJ ; CochonneauD ; FougerayS ; OliverL ; GeraldoF ; Terme et al. , Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside., *Oncotarget*, 2016, 7, 41172-41185

ForbesJF ; Sestakl ; Howella ; BonanniB ; BundredN ; Levy et al. , Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial., *Lancet*, 2016, 387, 866-73

FrenelJS ; BallyO ; BourboulouxE ; Berton-RigaudD ; CamponeM ; Bachelot et al. , [Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases]., *Bull Cancer*, 2016, 103, 507-10

FuY ; JoveletC ; FilleronT ; PedreroM ; Mottén ; Boursin et al. , Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations., *Cancer Res.*, 2016, 76, 5954-5961

Goineau, A ; Supiot, S , Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer: Reply., *Clin Nucl Med*, 2016, 41, 746-7

GolmardL ; DelnatteC ; LaugéA ; MoncoutierV ; LefolC ; Abidallah et al. , Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations., *Oncogene*, 2016, 35, 1324-7

González-MartínA ; PautierP ; MahnerS ; RauJ ; ColomboN ; Ottevanger et al. , Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial., *Int. J. Gynecol. Cancer*, 2016, 26, 898-905

GoulonD ; NecibH ; HenaffB ; RousseauC ; CarlierT ; Kraeber-Bodere et al. , Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer., *Front Med (Lausanne)*, 2016, 3, 19

GourmelonC ; BourienH ; AugereauP ; PatsourisA ; FrenelJS ; Campone et al. , Vinflunine for the treatment of breast cancer., *Expert Opin Pharmacother*, 2016, 17, 1817-23

Grossi, F ; Bennouna, J ; Havel, L ; Hochmair, M ; Almodovar, T , Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries., *Curr Med Res Opin*, 2016, 32, 1577-84

GruenbergerT ; BeetsG ; Van LaethemJL ; RougierP ; CervantesA ; Douillard et al. , Treatment sequence of synchronously (liver) metastasized colon cancer., *Dig Liver Dis*, 2016, 48, 1119-23

Guérard, F ; Lee, YS ; Baidoo, K ; Gestin, JF ; Brechbiel, MW , Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts., *Chemistry*, 2016, 22, 12332-9

GuillonneauM ; ParisF ; DutoitS ; EstéphanH ; BénéteauE ; Huot et al. , Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response., *FASEB J.*, 2016, 30, 2899-914

GustinP ; TremolieresP ; PeyragaG ; HureauJ ; MegeM ; Paumier et al. , 146P: The potential role for consolidative radiotherapy in oligometastatic non small cell lung cancer through the prism of pattern of failure analysis., *J Thorac Oncol*, 2016, 11, S121

HaddyN ; DialloS ; El-FayechC ; SchwartzB ; PeinF ; Hawkins et al. , Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study., *Circulation*, 2016, 133, 31-8

HalimeZ ; FrindelM ; CamusN ; OrainPY ; LacombeM ; Bernardeau et al. , Correction: New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative., *Org. Biomol. Chem.*, 2016, 14, 3838

HarterP ; JohnsonT ; Berton-RigaudD ; ParkSY ; FriedlanderM ; Del Campo et al. , BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study., *Gynecol. Oncol.*, 2016, 140, 443-9

HeinemannV ; RiveraF ; O'NeilBH ; StintzingS ; KoukakisR ; Terwey et al. , A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer., *Eur. J. Cancer*, 2016, 67, 11-20

Hennequin, C ; Rio, E ; Mahé, MA , [Radiotherapy of skin cancers]., *Cancer Radiother*, 2016, 20 Suppl, S249-55

HennequinC ; BarillotI ; AzriaD ; BelkacémiY ; BolletM ; Chauvet et al. , [Radiotherapy of breast cancer]., *Cancer Radiother*, 2016, 20 Suppl, S139-46

Henriques De FigueiredoB ; FortpiedC ; MenisJ ; LefebvreJL ; BarzanL ; de Raucourt et al. , Long-term update of the 24954 EORTC phase III trial on larynx preservation., *Eur. J. Cancer*, 2016, 65, 109-12

HortobagyiGN ; ChenD ; PiccartM ; RugoHS ; BurrisHA ; Pritchard et al. , Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2., *J. Clin. Oncol.*, 2016, 34, 419-26

HortobagyiGN ; StemmerSM ; BurrisHA ; YapYS ; SonkeGS ; Paluch-Shimon et al. , Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer., *N. Engl. J. Med.*, 2016, 375, 1738-1748

HouotM ; PilmisB ; Thepot-SeegersV ; SuardC ; PotierC ; Postaire et al. , Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study., *Eur. J. Pediatr.*, 2016, 175, 659-65

HouvenaeghelG ; BoherJM ; ReyalF ; CohenM ; GarbayJR ; Classe et al. , Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes., *Eur. J. Cancer*, 2016, 67, 106-118

HouvenaeghelG ; ClasseJM ; GarbayJR ; GiardS ; CohenM ; Faure et al. , Survival impact and predictive factors of axillary recurrence after sentinel biopsy., *Eur. J. Cancer*, 2016, 58, 73-82

HouvenaeghelG ; SabatierR ; ReyalF ; ClasseJM ; GiardS ; Charitansky et al. , Axillary lymph node micrometastases decrease triple-negative early breast cancer survival., *Br. J. Cancer*, 2016, 115, 1024-1031

ImbsDC ; DiérasV ; BachelotT ; CamponeM ; IsambertN ; Joly et al. , Pharmacokinetic interaction between pazopanib and cisplatin regimen., *Cancer Chemother. Pharmacol.*, 2016, 77, 385-92

JacotW ; PonsE ; FrenelJS ; GuiuS ; LevyC ; Heudel et al. , Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases., *Breast Cancer Res. Treat.*, 2016, 157, 307-318

JanorayG ; PointreauY ; GaraudP ; ChapetS ; AlfonsiM ; Sire et al. , Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation., *J. Natl. Cancer Inst.*, 2016, 108,

JarryU ; ChauvinC ; JoallandN ; LégerA ; MinaultS ; Robard et al. , Stereotaxic administrations of allogeneic human V $\alpha$ 9V $\beta$ 2 T cells efficiently control the development of human glioblastoma brain tumors., *Oncoimmunology*, 2016, 5, e1168554

Jonchère, B ; Vétillard, A ; Toutain, B ; Guette, C ; Coqueret, O , [Contribution to tumor escape and chemotherapy response: A choice between senescence and apoptosis in heterogeneous tumors]., *Bull Cancer*, 2016, 103, 73-86

Jouglar E ; Thomas L ; de la Rochefordière A ; Noël G ; Le Blanc-Onfroy M ; Delpon et al. , Toxicity and early clinical outcomes in cervical cancer following extended field helical tomotherapy to para-aortic lymph nodes., *Cancer Radiother*, 2016, 20, 794-800

Jouglar E ; Wagner A ; Delpon G ; Champion L ; Meingan P ; Bernier et al. , Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation., *PLoS ONE*, 2016, 11, e0164643

Kamoun A ; Idbaih A ; Dehais C ; Elarouci N ; Carpentier C ; Letouzé et al. , Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas., *Nat Commun*, 2016, 7, 11263

Kentish-Barnes N ; Seegers V ; Legriels S ; Cariou A ; Jaber S ; Lefrant et al. , CAESAR: a new tool to assess relatives' experience of dying and death in the ICU., *Intensive Care Med*, 2016, 42, 995-1002

Kepenekian V ; Elias D ; Passot G ; Mery E ; Goere D ; Delroeux et al. , Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study., *Eur. J. Cancer*, 2016, 65, 69-79

Klionsky DJ ; Abdelmohsen K ; Abe A ; Abedin MJ ; Abeliovich H ; Acevedo Arozena et al. , Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)., *Autophagy*, 2016, 12, 1-222

Kong A ; Rea D ; Ahmed S ; Beck JT ; López López R ; Biganzoli et al. , Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen., *Oncotarget*, 2016, 7, 37680-37692

Kotecki N ; Hiret S ; Etienne PL ; Penel N ; Tresch E ; François et al. , First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control., *Oncology*, 2016, 90, 88-96

Kraeber-Bodere, F ; Bailly, C ; Chérel, M ; Chatal, JF , ImmunoPET to help stratify patients for targeted therapies and to improve drug development., *Eur. J. Nucl. Med. Mol. Imaging*, 2016, 43, 2166-2168

Kraeber-Bodéré, F ; Barbet, J ; Chatal, JF , Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?, *J. Nucl. Med.*, 2016, 57, 329-31

Lafond C ; Chiavassa S ; Bertaut C ; BouSSION N ; Chapel N ; Chapron et al. , DEMAT: A multi-institutional dosimetry audit of rotational and static intensity-modulated radiotherapy., *Phys Med*, 2016, 32, 664-70

Lambaudie E ; Houvenaeghel G ; Ziouèche A ; Knight S ; Dravet F ; Garbay et al. , Exclusive intraoperative radiotherapy for invasive breast cancer in elderly patients (>70 years): proportion of eligible patients and local recurrence-free survival., *BMC Surg*, 2016, 16, 74

Laprie A ; Padovani L ; Bernier V ; Supiot S ; Huchet A ; Ducassou et al. , [Radiotherapy for paediatric cancers]., *Cancer Radiother*, 2016, 20 Suppl, S216-26

Lassalle A ; Thomaré P ; Fronteau C ; Mahé B ; Jubé C ; Blin et al. , Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study., *Ann. Oncol.*, 2016, 27, 314-8

Lassau N ; Coiffier B ; Kind M ; Vilgrain V ; Lacroix J ; Cuiet et al. , Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab., *Ann. Oncol.*, 2016, 27, 1922-8

Latorzeff I ; Antoni D ; Gaudaire-Josset S ; Feuvret L ; Tallet-Richard A ; Truc et al. , [Radiotherapy for brain metastases]., *Cancer Radiother*, 2016, 20 Suppl, S80-7

Launey Y ; Larmet R ; Nessler N ; Malledant Y ; Palpacuer C ; Seguin et al. , The Accuracy of Temperature Measurements Provided by the Edwards Lifesciences Pulmonary Artery Catheter., *Anesth. Analg.*, 2016, 122, 1480-3

LavouéV ; FritelX ; AntoineM ; BeltjensF ; BendifallahS ; Boisserie-Lacroix et al. , Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text., *Eur. J. Obstet. Gynecol. Reprod. Biol.*, 2016, 200, 16-23

LawrensonK ; KarS ; McCueK ; KuchenbaeckerK ; MichailidouK ; Tyrer et al. , Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus., *Nat Commun*, 2016, 7, 12675

Le BourgeoisA ; PeterlinP ; GuillaumeT ; DelaunayJ ; DuquesneA ; Le Gouill et al. , Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults., *Biol. Blood Marrow Transplant.*, 2016, 22, 1473-1479

Le GuellecS ; DecouvelaereAV ; FilleronT ; Valol ; Charon-BarraC ; Robin et al. , Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database., *Am. J. Surg. Pathol.*, 2016, 40, 896-908

Le PenJ ; LaurentM ; SarosiekK ; VuillierC ; GautierF ; Montessuit et al. , Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL., *Cell Death Dis*, 2016, 7, e2083

LebellecL ; BertucciF ; Tresch-BruneelE ; BompasE ; ToironY ; Camoin et al. , Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)., *Oncotarget*, 2016, 7, 73984-73994

LefebvreC ; BachelotT ; FilleronT ; PedreroM ; CamponeM ; Soria et al. , Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis., *PLoS Med.*, 2016, 13, e1002201

Libois, V ; Mahé, MA ; Rio, E ; Maingon, P , [Clinical to target volume margins determination in radiotherapy for anal cancers]., *Cancer Radiother*, 2016, 20, 645-50

LimentaniSA ; CamponeM ; DorvalT ; CuriglianoG ; de BoerR ; Vogel et al. , A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors., *Breast Cancer Res. Treat.*, 2016, 156, 319-30

LionM ; HarléA ; SalleronJ ; RamacciC ; CamponeM ; Merlin et al. , Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer., *Oncol Lett*, 2016, 12, 2028-2032

LiW ; O'ShaughnessyJ ; HayesD ; CamponeM ; BondarenkoI ; Zbarskaya et al. , Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer., *Clin. Cancer Res.*, 2016, 22, 6002-6009

MagrangeasF ; KuiperR ; Avet-LoiseauH ; GouraudW ; Guérin-CharbonnelC ; Ferrer et al. , A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma., *Clin. Cancer Res.*, 2016, 22, 4350-4355

Mahé, MA ; Barillot, I ; Chauvet, B , [Guidelines for external radiotherapy and brachytherapy: 2nd edition]., *Cancer Radiother*, 2016, 20 Suppl, S4-7

MantziariS ; GronnierC ; PasquerA ; GagnièreJ ; ThéreauxJ ; Demartines et al. , Incidence and Risk Factors Related to Symptomatic Venous Thromboembolic Events After Esophagectomy for Cancer., *Ann. Thorac. Surg.*, 2016, 102, 979-984

Marchanda ; Georgin-MègèM ; CellierP ; MartinL ; Avenel-AudranM ; Le Corre et al. , Exemestane-induced radiation recall dermatitis and morbilliform rash., *J. Dermatol.*, 2016, 43, 575-6

MarkarSR ; GronnierC ; DuhamelA ; PasquerA ; ThéreauxJ ; Chalret du Rieu et al. , Significance of Microscopically Incomplete Resection Margin After Esophagectomy for Esophageal Cancer., *Ann. Surg.*, 2016, 263, 712-8

MarkarSR ; GronnierC ; PasquerA ; DuhamelA ; BealH ; Théreaux et al. , Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study., *Eur. J. Cancer*, 2016, 56, 59-68



MartinezA ; NgoC ; LeblancE ; GouyS ; LuyckxM ; Darai et al. , Surgical Complexity Impact on Survival After Complete Cytoreductive Surgery for Advanced Ovarian Cancer., *Ann. Surg. Oncol.*, 2016, 23, 2515-21

MartinM ; FumoleauP ; DewarJA ; AlbanellJ ; LimentaniSA ; Campone et al. , Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., *Ann. Oncol.*, 2016, 27, 1249-56

MaX ; Le TeuffG ; LacasB ; TsaoMS ; GrazianoS ; Pignon et al. , Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis., *J Thorac Oncol*, 2016, 11, 850-61

MazeronR ; GouyS ; ChargariC ; Rivin Del CampoE ; DumasI ; Mervoyer et al. , Post radiation hysterectomy in locally advanced cervical cancer: Outcomes and dosimetric impact., *Radiother Oncol*, 2016, 120, 460-466

MénagerJ ; GorinJB ; FichouN ; GouardS ; MorgensternA ; Bruchertseifer et al. , [Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity]., *Med Sci (Paris)*, 2016, 32, 362-9

MessageM ; MirabelX ; TreschE ; PaumierA ; VendrelyV ; Dahan et al. , Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial., *BMC Cancer*, 2016, 16, 318

MeyersM ; GrangerB ; HermanP ; JanotF ; GarrelR ; Fakhry et al. , Head and neck adenoid cystic carcinoma: A prospective multicenter REFCOR study of 95 cases., *Eur Ann Otorhinolaryngol Head Neck Dis*, 2016, 133, 13-7

MirO ; BrodowiczT ; ItalianoA ; WalletJ ; BlayJY ; Bertucci et al. , Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial., *Lancet Oncol.*, 2016, 17, 1732-1742

MirO ; CropetC ; ToulmondeM ; CesneAL ; MolimardM ; Bompas et al. , Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial., *Lancet Oncol.*, 2016, 17, 632-41

MirzaMR ; MonkBJ ; HerrstedtJ ; OzaAM ; MahnerS ; Redondo et al. , Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer., *N. Engl. J. Med.*, 2016, 375, 2154-2164

MontoirD ; Barillé-NionS ; TonnerreA ; JuinP ; DuflosM ; Bazin et al. , Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90., *Eur J Med Chem*, 2016, 119, 17-33

MorganG ; LambertiniM ; KourieHR ; AmaraIT ; ArgilesG ; Banerjee et al. , Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)., *ESMO Open*, 2016, 1, e000107

MouttonS ; FergelotP ; NaudionS ; CordierMP ; SoléG ; Guerineau et al. , Otopalatodigital spectrum disorders: refinement of the phenotypic and mutational spectrum., *J. Hum. Genet.*, 2016, 61, 693-9

MyriantopoulosV ; CartronPF ; LiutkeviciusZ ; KlimauskasS ; MatulisD ; Bronner et al. , Tandem virtual screening targeting the SRA domain of UHRF1 identifies a novel chemical tool modulating DNA methylation., *Eur J Med Chem*, 2016, 114, 390-6

Naudet, F ; Palpacuer, C ; Bousageon, R ; Laviolle, B , Evaluation in alcohol use disorders - insights from the nalmefene experience., *BMC Med*, 2016, 14, 119

NobletC ; ChiavassaS ; SmekensF ; SarrutD ; PassalV ; Suhard et al. , Validation of fast Monte Carlo dose calculation in small animal radiotherapy with EBT3 radiochromic films., *Phys Med Biol*, 2016, 61, 3521-35

NosC ; CloughKB ; BonnierP ; LasryS ; Le BouedecG ; Flipo et al. , Upper outer boundaries of the axillary dissection. Result of the SENTIBRAS protocol: Multicentric protocol using axillary reverse mapping in breast cancer patients requiring axillary dissection., *Eur J Surg Oncol*, 2016, 42, 1827-1833

OhnleiterT ; MahéMA ; BiauJ ; WdowczykD ; ClavierJB ; Antoni et al. , [Frameless set-up with ExacTrac(®) system for stereotactic radiotherapy of brain metastasis: Descriptive study from five French centres]., *Cancer Radiother*, 2016, 20, 768-775

O'Shaughnessy J ; Camponi M ; Brain E ; Neven P ; Hayes D ; Bondarenko et al. , Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer., *Ann. Oncol.*, 2016, 27, 106-13

Oudard S ; Geoffrois L ; Guillot A ; Chevreau C ; Deville J L ; Falkowski et al. , Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in METastatic RCC (RESUME) Study., *Eur. J. Cancer*, 2016, 62, 28-35

Paillocher N ; Florczak A S ; Richard M ; Classe J M ; Oger A S ; Raro et al. , Evaluation of mastectomy with immediate autologous latissimus dorsi breast reconstruction following neoadjuvant chemotherapy and radiation therapy: A single institution study of 111 cases of invasive breast carcinoma., *Eur J Surg Oncol*, 2016, 42, 949-55

Paumier A ; Marquis A ; Trémolières P ; Lacombe M ; Capitain O ; Septans et al. , [Prognostic value of the metabolically active tumour volume]., *Cancer Radiother*, 2016, 20, 24-9

Pécot J ; Maillet L ; Le Pen J ; Vuillier C ; Trécesson S C ; Fétiveau et al. , Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance., *Cell Rep*, 2016, 17, 3347-3358

Perrier L ; Morelle M ; Pommier P ; Boisselier P ; Coche-Dequeant B ; Gallocher et al. , Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer., *Int. J. Radiat. Oncol. Biol. Phys.*, 2016, 95, 654-62

Pichon B ; Champion L ; Delpon G ; Thillays F ; Carrie C ; Cellier et al. , High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study., *Int. J. Radiat. Oncol. Biol. Phys.*, 2016, 96, 840-847

Piperno-Neumann S ; Le Deley M C ; Rédini F ; Pacquement H ; Marec-Bérard P ; Petit et al. , Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial., *Lancet Oncol.*, 2016, 17, 1070-1080

Pointreau Y ; Lafond C ; Legouté F ; Trémolières P ; Servagi-Vernat S ; Giraud et al. , [Radiotherapy of larynx cancers]., *Cancer Radiother*, 2016, 20 Suppl, S131-5

Pointreau Y ; Lafond C ; Trémolières P ; Legouté F ; Servagi-Vernat S ; Giraud et al. , [Radiotherapy of hypopharynx cancers]., *Cancer Radiother*, 2016, 20 Suppl, S126-30

Pouessel D ; Chevret S ; Rolland F ; Gravis G ; Geoffrois L ; Roubaud et al. , Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?, *Eur. J. Cancer*, 2016, 54, 69-74

Poulain P ; Berleur M P ; Lefki S ; Lefebvre D ; Chvetzoff G ; Serra et al. , Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain)., *J Pain Symptom Manage*, 2016, 52, 626-636.e1

Pulford D J ; Harter P ; Floquet A ; Barrett C ; Suh D H ; Friedlander et al. , Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study., *BMC Med Ethics*, 2016, 17, 63

Rajerison H ; Faye D ; Roumesy A ; Louaisil N ; Boeda F ; Faivre-Chauvet et al. , Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agents., *Org. Biomol. Chem.*, 2016, 14, 2121-6

Ravaud A ; Motzer R J ; Pandha H S ; George D J ; Pantuck A J ; Patel et al. , Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy., *N. Engl. J. Med.*, 2016, 375, 2246-2254

Reck M ; Rodríguez-Abreu D ; Robinson A G ; Hui R ; Csizi T ; Fülöp et al. , Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer., *N. Engl. J. Med.*, 2016, 375, 1823-1833

Renaudeau C ; Lefebvre-Lacoeuille C ; Champion L ; Dravet F ; Descamps P ; Ferron et al. , Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study., *Breast*, 2016, 28, 54-9

RenfroLA ; LoupakisF ; AdamsRA ; SeymourMT ; HeinemannV ; Schmoll et al. , Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database., *J. Clin. Oncol.*, 2016, 34, 144-50

Rio, E ; Mornex, F ; Peiffert, D ; Huertas, A , [Hepatic tumors and radiotherapy]., *Cancer Radiother*, 2016, 20 Suppl, S174-8

RobbWB ; MessengerM ; DahanL ; MornexF ; MaillardE ; D'Journo et al. , Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone., *Br J Surg*, 2016, 103, 117-25

RousseauC ; RousseauT ; MathieuC ; LacosteJ ; PotironE ; Aillet et al. , Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data., *Eur. J. Nucl. Med. Mol. Imaging*, 2016, 43, 1849-56

RousselotP ; CoudéMM ; GokbugetN ; Gambacorti PasseriniC ; HayetteS ; Cayuela et al. , Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL., *Blood*, 2016, 128, 774-82

SabianiL ; HouvenaeghelG ; HeinemannM ; Reyalf ; ClasseJM ; Cohen et al. , Breast cancer in young women: Pathologic features and molecular phenotype., *Breast*, 2016, 29, 109-16

Saito, K ; Nakayama, E ; Valmori, D , Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients., *PLoS ONE*, 2016, 11, e0150623

Sardaro, A ; Saito, K ; Nakayama, E ; Valmori, D , Correction: Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients., *PLoS ONE*, 2016, 11, e0160538

SargosP ; StoeckleE ; Henriques de FigueiredoB ; AntoineM ; DelannesM ; Mervoyer et al. , [Radiotherapy for retroperitoneal sarcomas]., *Cancer Radiother*, 2016, 20, 677-84

SchulerM ; YangJC ; ParkK ; KimJH ; Bennounaj ; Chen et al. , Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial., *Ann. Oncol.*, 2016, 27, 417-23

SébilléV ; HardouinJB ; GiralM ; Bonnaud-AntignacA ; TessierP ; Papuchon et al. , Prospective, multicenter, controlled study of quality of life, psychological adjustment process and medical outcomes of patients receiving a preemptive kidney transplant compared to a similar population of recipients after a dialysis period of less than three years--The PreKit-QoL study protocol., *BMC Nephrol*, 2016, 17, 11

SeegersV ; TouchetteE ; DionneG ; PetitD ; SeguinJR ; Montplaisir et al. , Short persistent sleep duration is associated with poor receptive vocabulary performance in middle childhood., *J Sleep Res*, 2016, 25, 325-32

SienaS ; TabereroJ ; BodokyG ; CunninghamD ; RiveraF ; Ruff et al. , Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial., *ESMO Open*, 2016, 1, e000041

SilvaVA ; LafontF ; Benhelli-MokraniH ; BretonML ; HulinP ; Chabot et al. , Rapid Diminution in the Level and Activity of DNA-Dependent Protein Kinase in Cancer Cells by a Reactive Nitro-Benzoxadiazole Compound., *Int J Mol Sci*, 2016, 17,

SinilnikovaOM ; DondonMG ; Eon-MarchaisS ; DamiolaF ; BarjhouxL ; Marcou et al. , GENESIS: a French national resource to study the missing heritability of breast cancer., *BMC Cancer*, 2016, 16, 13

SoudayV ; KoningNJ ; PerezB ; GrelonF ; MercatA ; Boer et al. , Correction: Enriched Air Nitrox Breathing Reduces Venous Gas Bubbles after Simulated SCUBA Diving: A Double-Blind Cross-Over Randomized Trial., *PLoS ONE*, 2016, 11, e0165771

SoudayV ; KoningNJ ; PerezB ; GrelonF ; MercatA ; Boer et al. , Enriched Air Nitrox Breathing Reduces Venous Gas Bubbles after Simulated SCUBA Diving: A Double-Blind Cross-Over Randomized Trial., *PLoS ONE*, 2016, 11, e0154761

SpielmannM ; DalencF ; PointreauY ; AzriaD ; ClasseJM ; Dromain et al. , [Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]., *Bull Cancer*, 2016, 103, 154-63

Staquet, H ; Dupouiron, D ; Nader, E ; Menei, P , Intracerebroventricular Pain Treatment with Analgesic Mixtures including Ziconotide for Intractable Pain., *Pain Physician*, 2016, 19, E905-15

SternbergC ; ArmstrongA ; PiliR ; NgS ; HuddartR ; Agarwal et al. , Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer., *J. Clin. Oncol.*, 2016, 34, 2636-43

StichelboutM ; DevismeL ; Franquet-Ansarth ; MassardierJ ; VinatierD ; Renaud et al. , SALL4 expression in gestational trophoblastic tumors: a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor., *Hum. Pathol.*, 2016, 54, 121-6

Sudour-Bonnange, H ; Rocourt, N ; Aubry, E ; Lervat, C ; Kerdraon, O , A Sex Cord-stromal Tumor, Specifically a Fibroma, Arising From the Uterine Corpus: A Case Report., *Int. J. Gynecol. Pathol.*, 2016, 35, 33-7

SupiotS ; DoréM ; RioE ; CellierP ; Mesguez-NeboutN ; Goineau et al. , [Role of radiotherapy in the management of node-positive prostate cancer]., *Cancer Radiother*, 2016, 20, 442-4

TabernerJ ; VyasM ; GiulianiR ; ArnoldD ; CardosoF ; Casali et al. , Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers., *ESMO Open*, 2016, 1, e000142

TabouretE ; BertucciF ; PiergaJY ; PetitT ; LevyC ; Ferrero et al. , MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study., *Oncotarget*, 2016, 7, 18531-40

TaieBJ ; Zaanana ; Le MalicotK ; JuliéC ; BlonsH ; Mineur et al. , Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial., *JAMA Oncol*, 2016, , 1-11

TensaoutiF ; DucassouA ; ChaltielL ; SevelyA ; BolleS ; Muracciole et al. , Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study., *Br J Radiol*, 2016, 89, 20160537

ThébaultS ; AgezM ; ChiX ; StojkoJ ; CuraV ; Telerman et al. , TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL., *Sci Rep*, 2016, 6, 19725

Thureau, S ; Vieillard, MH ; Supiot, S ; Lagrange, JL , [Radiotherapy of bone metastases]., *Cancer Radiother*, 2016, 20 Suppl, S227-34

TouchefeuY ; Provost-DewitteM ; LecomteT ; MorelA ; Valol ; Mosnier et al. , Clinical, histological, and molecular risk factors for cancer recurrence in patients with stage II colon cancer., *Eur J Gastroenterol Hepatol*, 2016, 28, 1394-1399

UngM ; Rouquettel ; FilleronT ; TaillandyK ; BrouchetL ; Bennouna et al. , Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung., *Clin Lung Cancer*, 2016, 17, 391-397

UyttenhoveF ; LangloisC ; CollinetP ; RubodC ; VerpillatP ; Bigot et al. , Deep infiltrating endometriosis: Should rectal and vaginal opacification be systematically used in MR imaging?, *Gynecol Obstet Fertil*, 2016, 44, 322-8

ValentinT ; Le CesneA ; Ray-CoquardI ; ItalianoA ; DecanterG ; Bompas et al. , Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)., *Eur. J. Cancer*, 2016, 56, 77-84

Valmori, D ; Ayyoub, M , Prospective strategies to combine conventional, targeted and immunotherapies in non-small cell lung cancer., *Oncoimmunology*, 2016, 5, e947175

Van CutsemE ; CervantesA ; AdamR ; SobreroA ; Van KriekenJH ; Aderka et al. , ESMO consensus guidelines for the management of patients with metastatic colorectal cancer., *Ann. Oncol.*, 2016, 27, 1386-422

van KriekenH ; DeansS ; HallJA ; NormannoN ; CiardielloF ; Douillard et al. , Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016., ESMO Open, 2016, 1, e000114

VanbockstaellJ ; CoquanE ; GouerantS ; AllouacheD ; FaveyrialA ; Noal et al. , How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study., Support Care Cancer, 2016, 24, 1131-8

Véquaud, E ; Desplanques, G ; Jézéquel, P ; Juin, P ; Barillé-Nion, S , Survivin contributes to DNA repair by homologous recombination in breast cancer cells., Breast Cancer Res. Treat., 2016, 155, 53-63

VerheydenC ; Pages-BouicE ; BalleyguierC ; CherelP ; LeporiD ; Laffargue et al. , Underestimation Rate at MR Imaging-guided Vacuum-assisted Breast Biopsy: A Multi-Institutional Retrospective Study of 1509 Breast Biopsies., Radiology, 2016, 281, 708-719

ViallardJF ; AgapeP ; BarlogisV ; CozonG ; FaureC ; Fouyssac et al. , Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial., BMC Immunol., 2016, 17, 34

VidalF ; Al ThaniH ; HaddadP ; LuyckxM ; StoeckleE ; Morice et al. , Which Surgical Attitude to Choose in the Context of Non-Resectability of Ovarian Carcinomatosis: Beyond Gross Residual Disease Considerations., Ann. Surg. Oncol., 2016, 23, 434-42

VidalF ; GuerbyP ; LuyckxM ; HaddadP ; StoeckleE ; Morice et al. , Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?, PLoS ONE, 2016, 11, e0147787

VigoritoE ; KuchenbaeckerKB ; BeesleyJ ; AdlardJ ; AgnarssonBA ; Andrulis et al. , Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers., PLoS ONE, 2016, 11, e0158801

VilleneuveL ; ThivoletA ; BakrinN ; MohamedF ; IsaacS ; Valette et al. , A new internet tool to report peritoneal malignancy extent. Peritoneal Malignancy Stage Evaluation (PROMISE) application., Eur J Surg Oncol, 2016, 42, 877-82

WangJ ; HechmatiG ; DongJ ; MaglinteGA ; BarberB ; Douillard et al. , Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer., Curr Med Res Opin, 2016, 32, 459-65

GravisG ; BoherJM ; JolyF ; SouliéM ; AlbigesL ; Priou et al. , Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial., Eur. Urol., 2016, 70, 256-62

WickW ; GorliaT ; BadyP ; PlattenM ; van den BentMJ ; Taphoorn et al. , Phase II Study of Radiotherapy and Temozolomide versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)., Clin. Cancer Res., 2016, 22, 4797-4806

WilkeC ; HoltanSG ; SharkeyL ; DeForT ; AroraM ; Premakanthan et al. , Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen., Radiother Oncol, 2016, 118, 65-71

ZinzindhouéC ; BertrandP ; Michela ; MonrigalE ; MiramandB ; Sterckers et al. , A Prospective Study on Skin-Sparing Mastectomy for Immediate Breast Reconstruction with Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma., Ann. Surg. Oncol., 2016, 23, 2350-6